Get the Stockscreener App
11.64
3.65%
0.41
After Hours:
11.41
-0.23
-1.98%
Mink Therapeutics Inc stock is traded at $11.64, with a volume of 5,846.
It is up +3.65% in the last 24 hours and up +5.15% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
See More
Previous Close:
$11.23
Open:
$11.16
24h Volume:
5,846
Relative Volume:
0.38
Market Cap:
$59.40M
Revenue:
-
Net Income/Loss:
$-12.49M
P/E Ratio:
-3.9261
EPS:
-2.9648
Net Cash Flow:
$-5.93M
1W Performance:
+1.85%
1M Performance:
+5.15%
6M Performance:
+6.69%
1Y Performance:
-15.35%
1-Day Range:
$11.16
$11.64
1-Week Range:
$10.82
$11.75
52-Week Range:
$8.4801
$16.98
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
11.64 | 59.30M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
MiNK Therapeutics (INKT) insider reports stock trades - Stock Titan
MiNK Therapeutics (INKT) Drops 6.1% to $11.06 on Biotech Sector WeaknessWyckoff Distribution - vinanet.vn
MiNK (INKT) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Reported Period; After Earnings: Shares Move Lower 3.11% in Latest TradingTech Earnings Analysis - vinanet.vn
MiNK Therapeutics Earnings Call Highlights ARDS Push - TipRanks
MiNK (INKT) Move: Moves 0.15% Up to $11.37 for the Current Session; Price Setup: Support at $10.80 and Resistance at $11.94 Frame the Range at the CloseAI Trade Signals - vinanet.vn
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.ca
Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst - MarketBeat
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat
INKT|Mink Therapeutics Inc|Price:11.680| - tradingkey.com
MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiNK Therapeutics (INKT) Slides 5.17% as Biotech Stock Tests Key Support at $10.45AAII Neutral - vinanet.vn
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha
MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
META_TITLE_QUOTE - Yahoo Finance
MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat
MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade
INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView
MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛
Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com
Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia
MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com
MiNK Reports $3.1 Million Second-Quarter Loss and Phase 2 ARDS Update - Quiver Quantitative
MiNK Therapeutics Q2 loss narrows on expense discipline - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - Investing News Network
MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia - Blockonomi
Transactions récentes par des initiés de Mink Therapeutics Inc. R (6Q40.F) - Yahoo Finance France
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium - The Manila Times
Liquidity Mapping Around (INKT) Price Events - Stock Traders Daily
MiNK Therapeutics to Report Second Quarter 2026 Financial Results and Provide Corporate Update on agenT-797 Clinical Progress - Quiver Quantitative
MiNK Therapeutics to Report Second Quarter 2026 Financial - GlobeNewswire
New agenT-797 lung-injury data due from MiNK Aug. 13 - Stock Titan
MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - MarketBeat
MiNK Therapeutics Q2 Results: Financials and Clinical Updates - scanx.trade
Mink Therapeutics to report Q2 results, host conference call and webcast - Bitget
INKT Q2'26 Earnings: revenue estimate is 0 USD - TradingView
MiNK Therapeutics (INKT) Climbs 5.7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
INKT Q1 2026 Earnings: Narrower-than-Expected Loss of -$0.57 Drives 0.77% Stock UptickEarnings Beat Streak - vinanet.vn
MiNK Therapeutics, Inc. Revenue Breakdown – NASDAQ:INKT - TradingView
MiNK Therapeutics (INKT) Gains Ground: Support Holds Above Key LevelTake Profit Levels - vinanet.vn
MiNK Therapeutics Q1 2026 Earnings: Narrower Loss than Expected Reflects Cost DisciplineQuarterly Earnings - dars.gov.et
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):